| Pros and cons of aminoglutethimide for advanced postmenopausal breast cancer. | |
| | |
MedLine Citation:
|
PMID: 6518295 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In a phase II clinical trial, 38 postmenopausal women with advanced breast cancer were treated with aminoglutethimide and replacement hydrocortisone. All women had previously received up to 4 modalities of endocrine therapy. Seventeen patients had also been treated with cytostatic drugs. Twenty-five percent of the 29 evaluable patients experienced objective tumor regression, lasting from 11 to more than 18 months. In 29% the disease was stabilized for 3 to more than 15 months. Toxicity was significant, necessitating drug withdrawal in 3 patients. One patient died within 3 weeks of therapy from multiple perforated gastric ulcers. Two patients developed herpes zoster within 4 weeks of treatment. Many side effects were minor and transient. However, treatment resulted in overt primary hypothyroidism in 25% of the evaluable patients and in a strongly increased need of acenocoumarin in all 3 patients on anticoagulant therapy. |
| | |
Authors:
|
P F Bruning; J G Bonfrèr; E Engelsman; E Hamersma-vd Linden; M de Jong-Bakker; W Nooyen |
Related Documents
:
|
9010425 - Treatment of syringomyelia associated with arachnoid scarring caused by arachnoiditis o... 21091935 - Portal hypertension: diagnosis and management with particular reference to variceal hem... 11720675 - A treatment scale for axillary management in breast cancer. 23089445 - The use of bioabsorbable staple-line reinforcement performing stapled hemorrhoidopexy t... 18022495 - Application of the timi risk score in ed patients with cocaine-associated chest pain. 21251705 - Standard cardiopulmonary resuscitation versus active compression-decompression cardiopu... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Breast cancer research and treatment Volume: 4 ISSN: 0167-6806 ISO Abbreviation: Breast Cancer Res. Treat. Publication Date: 1984 |
Date Detail:
|
Created Date: 1985-03-07 Completed Date: 1985-03-07 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 8111104 Medline TA: Breast Cancer Res Treat Country: NETHERLANDS |
Other Details:
|
Languages: eng Pagination: 289-95 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aminoglutethimide
/
adverse effects*,
therapeutic use* Breast Neoplasms / drug therapy* Female Humans Hydrocortisone / therapeutic use Menopause* Middle Aged Thyrotropin / blood |
| Chemical | |
Reg. No./Substance:
|
125-84-8/Aminoglutethimide; 50-23-7/Hydrocortisone; 9002-71-5/Thyrotropin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Value of 8S/4S fractionation of estrogen receptors (ER) for prediction of response to hormonal manip...
Next Document: The efficacy of bone scanning in the follow-up of patients with operable breast cancer.